SELECT PUBLICATIONS

Ahn JH Sr et al. Phase II study of combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002;Abstract 2030.

Albain S et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Blum JL et al. A Phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naïve patients. Breast Cancer ResTreat 2004;88(Suppl 1);Abstract 5053.

Chlebowski RT et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). Presentation. ASCO 2005. Abstract 10.

Domenech G et al. Vinorelbine/capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC). Proc ASCO 2001;Abstract 1939.

Estevez LG et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Proc ASCO 2004;Abstract 748.

Fallowfield L et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22(21):4261-71. Abstract

Fountzilas G et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as f irst-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15(10):1517-26. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Ghosn M et al. Final results of a phase II study of vinorelbine in combination with capecitabine as f irst line chemotherapy for metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 270.

Gligorov J et al. Capecitabine and oral vinorelbine in metastatic breast cancer: Preliminary experience. Proc ASCO 2003;Abstract 351.

Hess DD et al. Phase I-II trial of capecitabine and vinorelbine in elderly patients (pts: > 65y) with metastatic breast cancer (MBC): SAKK 25/99 for the Swiss Group of Clinical Cancer Research, Berne, Switzerland. Proc ASCO 2002;Abstract 2915.

Howell A, on behalf of the ATAC Trialists’ Group. ATAC (Arimidex, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior eff icacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium 2004. Presentation. Abstract 1.

Howell A et al. Results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Love NH et al. Preferences for oral versus parenteral antitumor therapy: A survey of patients with metastatic breast cancer. Oncology Nursing Society Congress 2005. No abstract available

Love NH et al. A “report card” on medical oncologists and oncology nurses: Survey of patients with metastatic breast cancer and companion surveys of medical oncologists and oncology nurses. San Antonio Breast Cancer Symposium 2004;Abstract 3069.

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005. No abstract available

O’Shaughnessy J et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior eff icacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Paley MF et al. Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast disease cancer. Proc ASCO 2005;Abstract 619.

Perez E. Further analysis of NCCTG-N9831. Presentation. Miami Breast Cancer Conference 2005. No abstract available

Stuart N et al. Vinorelbine and capecitabine (VX) for advanced breast cancer — A phase II study showing good activity and potential for further development. Proc ASCO 2003;Abstract 183.

Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presentation. ASCO 2005;Abstract 511.

Xu B et al. Capecitabine (X) combined with vinorelbine (V) in Chinese patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 741.